| Quarter (USD) | Sep 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 94.83 mm | 94.83 mm | 94.83 mm | 94.83 mm | 94.83 mm | |
| Cash burn (monthly) | 18.92 mm | 1.58 mm | 9.74 mm | 9.73 mm | 5.71 mm | |
| Cash used (since last report) | 52.93 mm | 4.43 mm | 27.25 mm | 27.22 mm | 15.97 mm | |
| Cash remaining | 41.89 mm | 90.39 mm | 67.57 mm | 67.61 mm | 78.86 mm | |
| Runway (months of cash) | 2.2 | 57.1 | 6.9 | 6.9 | 13.8 | |
| 13F holders | Current |
|---|---|
| Total holders | 72 |
| Opened positions | 33 |
| Closed positions | 10 |
| Increased positions | 20 |
| Reduced positions | 9 |
| 13F shares | Current |
|---|---|
| Total value | 99.47 bn |
| Total shares | 45.25 mm |
| Total puts | 4.23 k |
| Total calls | 65.00 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| TCG Crossover GP II | 20.76 mm | $40.90 mm |
| Venrock Healthcare Capital Partners III | 5.90 mm | $11.86 mm |
| BML Capital Management | 1.97 mm | $13.49 bn |
| REGN Regeneron Pharmaceuticals | 1.81 mm | $3.18 mm |
| BEN Franklin Resources | 1.76 mm | $12.07 bn |
| VR Adviser | 1.47 mm | $10.06 bn |
| BLK BlackRock | 1.41 mm | $9.67 bn |
| Frazier Life Sciences Management | 1.07 mm | $7.34 bn |
| BML Investment Partners | 1.05 mm | $11.72 mm |
| Vanguard | 1.01 mm | $6.92 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jul 24 | Braden Michael Leonard | Common Stock | Buy | Acquire P | Yes | No | 7.15 | 85,800 | 613.47 k | 2,268,064 |
| 18 Jul 24 | Braden Michael Leonard | Common Stock | Buy | Acquire P | Yes | No | 9.1149 | 80,718 | 735.74 k | 2,182,264 |
| 17 Jul 24 | Braden Michael Leonard | Common Stock | Buy | Acquire P | Yes | No | 7.7459 | 135,546 | 1.05 mm | 2,101,546 |
| 17 Jun 24 | Scopa James Paul | Stock Option Common Stock | Grant | Acquire A | No | No | 7.32 | 10,520 | 77.01 k | 10,520 |
| 17 Jun 24 | Rabia Gurses Ozden | Stock Option Common Stock | Grant | Acquire A | No | No | 7.32 | 85,000 | 622.20 k | 85,000 |
